DOSAGE AND ADMINISTRATION
TRISENOX® should be diluted with 100 to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The TRISENOX® ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Do not save any unused portions for later administration. Do not mix TRISENOX® with other medications.
TRISENOX® should be administered intravenously over 1-2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. A central venous catheter is not required.
STABILITY
After dilution, TRISENOX® is chemically and physically stable when stored for 24 hours at room temperature and 48 hours when refrigerated.
DOSING REGIMEN
TRISENOX® is recommended to be given according to the following schedule:
Induction Treatment Schedule: TRISENOX® should be administered intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Total induction dose should not exceed 60 doses. Consolidation Treatment Schedule: Consolidation treatment should begin 3 to 6 weeks after completion of induction therapy. TRISENOX® should be administered intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.
HANDLING AND DISPOSAL
Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1-7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
|
